Jack Li

Senior Associate
Norton Rose Fulbright Hong Kong
jack.li@nortonrosefulbright.com
Jack
Li
Jack Li
Hong Kong SAR
38/F Jardine House
1 Connaught Place
Central
Hong Kong SAR
+852 34052549

Jack Li is a corporate finance lawyer based in Hong Kong. He has a particular focus in IPOs and compliance and regulatory matters associated with listed companies in Hong Kong.

Representative experience

Hong Kong IPO and listing

  • Shanghai Seer Intelligent Technology (6106.HK): H-share Main Board IPO and HK$1.07 billion global offering. Represented CICC.

  • Star Sports Medicine (1609.HK): H-share Main Board IPO and HK$829.6 million global offering. Represented CITIC Securities and CCBI.

  • Chifeng Jilong Gold Mining (6693.HK; 600988.SH): H-share Main Board IPO and HK$2.8 billion global offering.  Represented the Company.

  • Xuanzhu Biopharmaceutical (2575.HK): H-share spin-off listing on Main Board and HK$780 million global offering.  Represented CICC.

  • 160 Health International (2656.HK): Main Board IPO and HK$400 million global offering.  Represented Shenwan Hongyuan and Zero2IPO.

  • Qilu Expressway (1576.HK): H-share Main Board IPO and HK$1.2 billion global offering.  Represented the Company.

  • Shandong Victorysoft : proposed H-share Main Board IPO.  A1 application filed.  Represented GF Capital.

  • PCI Technology Group: proposed H-share Main Board IPO.  A1 application filed.  Represented GF Capital, CITIC Securities and ABCI.

  • Guangdong Asensing Technology: proposed H-share Main Board IPO.  A1 application filed.  Represented CICC and China Securities International.

  • A late-stage biopharmaceutical company focused on tumor-infiltrating lymphocytes and innovative immune cell therapies: proposed H-share Main Board IPO.  A1 application filed.  Represented CICC and DBS Asia Capital.

  • Zhejiang IPLUSMOBOT Technology: proposed H-share Main Board IPO.  A1 application filed.  Represented CICC.

  • Shenzhen Vergiga Semiconductor: proposed H-share Main Board IPO.  A1 application filed.  Represented GF Capital.

  • A developer of medical imaging equipment and software specializing in interventional diagnostic and therapeutic equipment and comprehensive workflow solutions: proposed H-share Main Board IPO.  A1 application filed.  Represented CICC and CMBCIC.

Other listings

  • Acted for Sogou Inc. (NYSE: SOGO) on the listing of ADS in the United States as special counsel as to Hong Kong law.

  • Acted for Central China Securities (1375.HK; 601375.SH) on the listing of A shares on the Shanghai Stock Exchange as to Hong Kong law.

Admissions

  • qualified in Hong Kong 2017

Languages

  • Cantonese
  • English
  • Mandarin Chinese
Bio